Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
- Sponsor
- Novartis
- Study ID
- NCT00546143
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- Omalizumab — DRUG
- Omalizumab — DRUG
- Omalizumab — DRUG
Study Details
This study will evaluate the safety and efficacy of omalizumab against asthma attacks in mild to moderate allergic asthma
Key Dates
- Start date
- Jul 31, 2007
- Status verified
- Sep 2010
- Primary completion
- Aug 31, 2008
Study Design
- Enrollment
- 32 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 1Omalizumab 900 mg
- Experimental: 2Omalizumab 1050 mg
- Experimental: 3Omalizumab 1200 mg
Primary Outcome Measure
Safety and tolerability of omalizumab assessed by AEs and SAEs
Related Studies
- Role of Genetic Factors in the Development of Lung DiseaseRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- Personalized Environment and Genes StudyRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent AsthmaRecruiting · Gelb, Arthur F., M.D. · Lakewood, California
- Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway InflammationPHASE1 · Recruiting · Benjamin Medoff · Boston, Massachusetts